growth arrest specific 2 like 2Genealiases: CILD41 · GAR17
Q-omics provides the consensus-scored GAS2L2 profile across patient tissues and cancer cell-line models. GAS2L2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GAS2L2 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, GAS2L2 RNA expression shows 10,932 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LUAD, and TGCT as cancer lineages where GAS2L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAS2L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAS2L2 survival associations across molecular data types. GAS2L2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAS2L2 RNA expression–survival associations across cancer types. High GAS2L2 expression shows unfavorable associations in KIRC, COAD, LGG and ACC, but favorable associations in ESCA and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GAS2L2 RNA expression.
This table summarizes GAS2L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GAS2L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAS2L2 shows lower tumor expression in LUAD, LUSC, BRCA, COAD and KICH and higher tumor expression in THCA. The LUAD box plot shows higher GAS2L2 RNA expression in normal versus tumor tissue (log2 FC = −1.371, t-test p < 0.001).
This table shows molecular features associated with GAS2L2 in patient tissues and cancer cell lines. In patient samples, GAS2L2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GAS2L2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
